Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Century Therapeutics Inc's Business Segments
Century Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 109
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 109 | 100% |
Description of Century Therapeutics Inc
Century Therapeutics Inc. is a cutting-edge biotechnology company that specializes in developing induced pluripotent stem cell (iPSC) technology for the treatment of various diseases, particularly cancer. The company was established in , and has since gained significant recognition for its pioneering work in the field of cellular immunotherapy.
One of the company's primary goals is to leverage the power of iPSCs to create off-the-shelf universal allogeneic cell therapies that can be effectively used in multiple patients without the need for individualized manufacturing. By using iPSCs, Century Therapeutics aims to overcome the limitations associated with current autologous cellular therapies, such as the time-consuming and costly process of patient-specific cell manufacturing.
Century Therapeutics is led by a team of accomplished scientists, researchers, and industry experts who bring together a wealth of knowledge and experience in cellular biology, immunology, and regenerative medicine. The company's leadership includes renowned individuals in the field, contributing to the credibility and reputation of Century Therapeutics.
The company's flagship platform, called iPSC allogeneic cell therapy, involves the reprogramming of adult cells into iPSCs. These iPSCs are then differentiated into various immune cell types, such as natural killer (NK) cells, T cells, and dendritic cells. By engineering these cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) specific for tumor antigens, Century Therapeutics aims to create powerful and specific immune cells capable of targeting and eliminating cancer cells.
One notable aspect of Century Therapeutics' approach is its collaboration with academic institutions, including the University of Pennsylvania and the Memorial Sloan Kettering Cancer Center. These partnerships provide access to cutting-edge research, clinical expertise, and innovative technologies, enhancing the company's ability to translate scientific discoveries into effective therapies.
In addition to its iPSC allogeneic cell therapy platform, Century Therapeutics is also actively involved in developing other novel technologies and therapeutic approaches. These include gene editing techniques, next-generation sequencing, and RNA interference, which hold the potential to further advance cellular immunotherapy and expand its application in treating various diseases beyond cancer.
Century Therapeutics has received substantial funding from reputable venture capital firms and strategic partners. The company's financial support enables it to accelerate research and development efforts, expand its manufacturing capabilities, advance clinical trials, and ultimately bring its innovative therapies to patients in need.
Overall, Century Therapeutics is a forward-thinking biotechnology company that is at the forefront of revolutionizing cellular immunotherapy. With its groundbreaking iPSC allogeneic cell therapy platform, strategic partnerships, and commitment to scientific excellence, the company is poised to make significant contributions in the field of regenerative medicine and transform the way cancer and other diseases are treated.
One of the company's primary goals is to leverage the power of iPSCs to create off-the-shelf universal allogeneic cell therapies that can be effectively used in multiple patients without the need for individualized manufacturing. By using iPSCs, Century Therapeutics aims to overcome the limitations associated with current autologous cellular therapies, such as the time-consuming and costly process of patient-specific cell manufacturing.
Century Therapeutics is led by a team of accomplished scientists, researchers, and industry experts who bring together a wealth of knowledge and experience in cellular biology, immunology, and regenerative medicine. The company's leadership includes renowned individuals in the field, contributing to the credibility and reputation of Century Therapeutics.
The company's flagship platform, called iPSC allogeneic cell therapy, involves the reprogramming of adult cells into iPSCs. These iPSCs are then differentiated into various immune cell types, such as natural killer (NK) cells, T cells, and dendritic cells. By engineering these cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) specific for tumor antigens, Century Therapeutics aims to create powerful and specific immune cells capable of targeting and eliminating cancer cells.
One notable aspect of Century Therapeutics' approach is its collaboration with academic institutions, including the University of Pennsylvania and the Memorial Sloan Kettering Cancer Center. These partnerships provide access to cutting-edge research, clinical expertise, and innovative technologies, enhancing the company's ability to translate scientific discoveries into effective therapies.
In addition to its iPSC allogeneic cell therapy platform, Century Therapeutics is also actively involved in developing other novel technologies and therapeutic approaches. These include gene editing techniques, next-generation sequencing, and RNA interference, which hold the potential to further advance cellular immunotherapy and expand its application in treating various diseases beyond cancer.
Century Therapeutics has received substantial funding from reputable venture capital firms and strategic partners. The company's financial support enables it to accelerate research and development efforts, expand its manufacturing capabilities, advance clinical trials, and ultimately bring its innovative therapies to patients in need.
Overall, Century Therapeutics is a forward-thinking biotechnology company that is at the forefront of revolutionizing cellular immunotherapy. With its groundbreaking iPSC allogeneic cell therapy platform, strategic partnerships, and commitment to scientific excellence, the company is poised to make significant contributions in the field of regenerative medicine and transform the way cancer and other diseases are treated.
Century Therapeutics Inc.: Comprehensive Overview of Segments, Products, and Services
Century Therapeutics Inc. is at the forefront of biotechnology innovation, particularly in the realm of cell therapy. By leveraging the capabilities of induced pluripotent stem cells (iPSCs), the company is dedicated to pioneering approaches that aim to transform regenerative medicine and tackle various challenging health conditions, especially cancer.
Segments
1. iPSC Technology
- Overview: At the core of Century Therapeutics mission lies the advanced utilization of iPSC technology. This groundbreaking approach allows for the reprogramming of somatic (adult) cells back into a pluripotent state. iPSCs possess the ability to develop into virtually any cell type in the body, providing a versatile foundation for therapeutic applications.
- Applications: The technology underpins the potential for tailored cellular therapies, which can be customized to meet individual patient needs, enhancing both efficacy and safety in treatment protocols.
2. Immune Cell Therapies
- Overview: Recognizing the immune systems critical role in combating diseases, Century Therapeutics prioritizes the development of immune cell therapies derived from iPSCs. This segment harnesses the potential to create an array of immune cells, including:
- T Cells: Engineered for targeted cancer therapies, with the goal of enhancing the body’s natural defenses against tumors.
- Natural Killer (NK) Cells: Utilizing the innate immune response to identify and destroy cancer cells with heightened efficiency.
- Dendritic Cells: Focused on stimulating robust immune responses by presenting antigens and activating T cells.
- Significance: These innovative therapies are positioned to redefine cancer treatment paradigms, offering novel solutions to patients with limited success from conventional therapies.
Products
1. Cell Therapy Candidates
- Description: Century Therapeutics has developed a diverse portfolio of cell therapy candidates targeting various malignancies and diseases. These therapies are specifically formulated to exploit the immune systems ability to discern and eradicate aberrant cells.
- Diversity: The pipeline includes candidates focused on high unmet medical needs, with strategic indications spanning across hematological malignancies and solid tumors.
2. Novel CAR-Macrophage Platform
- Innovation: This proprietary platform integrates chimeric antigen receptor (CAR) technology with macrophages, which are critical players in the immune response. By equipping macrophages with CARs, Century aims to enhance their ability to identify and eliminate tumor cells.
- Potential: This approach is anticipated to significantly amplify the efficacy of existing cell therapies, ushering in a new era of treatment options for patients with aggressive or treatment-resistant cancers.
3. Proprietary Manufacturing Technologies
- Focus: To support their ambitious cell therapy development goals, Century Therapeutics utilizes proprietary techniques for large-scale manufacturing of iPSC-derived cells.
- Efficiency: These manufacturing technologies are designed not only for scalability but also for maintaining the integrity and quality of cells produced, thereby ensuring a steady supply of high-quality therapies to meet clinical and commercial demands.
Services
1. Research Collaboration
- Partnerships: Century Therapeutics actively engages in collaborations with leading academic institutions, biopharmaceutical companies, and research entities. These strategic partnerships are fundamental to driving advances in the field of cell therapy.
- Goals: Through collaborative research efforts, the company aims to accelerate the discovery and development of new therapeutic candidates, expediting their journey from the lab to clinical application.
2. Personalized Medicine
- Objective: Century Therapeutics is committed to pioneering personalized medicine approaches in cell therapy. By utilizing iPSC technology and tailored therapies, the company seeks to address the unique biological and genetic characteristics of individual patients.
- Benefits: This focus maximizes treatment effectiveness and minimizes the risk of adverse reactions, thereby aligning with the broader trend toward personalized healthcare solutions.
3. Clinical Trials
- Commitment to Evidence: Conducting comprehensive clinical trials is crucial for validating the safety and efficacy of their therapies. Century Therapeutics collaborates with prominent medical centers to implement rigorous trial designs.
- Structure: These trials are meticulously structured to monitor the outcomes of cell therapies, following strict regulatory guidelines to ensure patient safety and scientific integrity prior to market introduction.
Summary
In summary, Century Therapeutics Inc. stands as a trailblazer in biotechnology, focusing on advanced iPSC technology and immune cell therapies to innovate treatment options for cancer and other diseases. Through their extensive product pipeline, cutting-edge CAR-macrophage platform, and proprietary manufacturing capabilities, the company is well-positioned to address pressing healthcare challenges. Their dedication to personalized medicine, robust research collaborations, and thorough clinical trials underscores their commitment to transforming regenerative medicine and improving patient outcomes.
Century Therapeutics Inc. is at the forefront of biotechnology innovation, particularly in the realm of cell therapy. By leveraging the capabilities of induced pluripotent stem cells (iPSCs), the company is dedicated to pioneering approaches that aim to transform regenerative medicine and tackle various challenging health conditions, especially cancer.
Segments
1. iPSC Technology
- Overview: At the core of Century Therapeutics mission lies the advanced utilization of iPSC technology. This groundbreaking approach allows for the reprogramming of somatic (adult) cells back into a pluripotent state. iPSCs possess the ability to develop into virtually any cell type in the body, providing a versatile foundation for therapeutic applications.
- Applications: The technology underpins the potential for tailored cellular therapies, which can be customized to meet individual patient needs, enhancing both efficacy and safety in treatment protocols.
2. Immune Cell Therapies
- Overview: Recognizing the immune systems critical role in combating diseases, Century Therapeutics prioritizes the development of immune cell therapies derived from iPSCs. This segment harnesses the potential to create an array of immune cells, including:
- T Cells: Engineered for targeted cancer therapies, with the goal of enhancing the body’s natural defenses against tumors.
- Natural Killer (NK) Cells: Utilizing the innate immune response to identify and destroy cancer cells with heightened efficiency.
- Dendritic Cells: Focused on stimulating robust immune responses by presenting antigens and activating T cells.
- Significance: These innovative therapies are positioned to redefine cancer treatment paradigms, offering novel solutions to patients with limited success from conventional therapies.
Products
1. Cell Therapy Candidates
- Description: Century Therapeutics has developed a diverse portfolio of cell therapy candidates targeting various malignancies and diseases. These therapies are specifically formulated to exploit the immune systems ability to discern and eradicate aberrant cells.
- Diversity: The pipeline includes candidates focused on high unmet medical needs, with strategic indications spanning across hematological malignancies and solid tumors.
2. Novel CAR-Macrophage Platform
- Innovation: This proprietary platform integrates chimeric antigen receptor (CAR) technology with macrophages, which are critical players in the immune response. By equipping macrophages with CARs, Century aims to enhance their ability to identify and eliminate tumor cells.
- Potential: This approach is anticipated to significantly amplify the efficacy of existing cell therapies, ushering in a new era of treatment options for patients with aggressive or treatment-resistant cancers.
3. Proprietary Manufacturing Technologies
- Focus: To support their ambitious cell therapy development goals, Century Therapeutics utilizes proprietary techniques for large-scale manufacturing of iPSC-derived cells.
- Efficiency: These manufacturing technologies are designed not only for scalability but also for maintaining the integrity and quality of cells produced, thereby ensuring a steady supply of high-quality therapies to meet clinical and commercial demands.
Services
1. Research Collaboration
- Partnerships: Century Therapeutics actively engages in collaborations with leading academic institutions, biopharmaceutical companies, and research entities. These strategic partnerships are fundamental to driving advances in the field of cell therapy.
- Goals: Through collaborative research efforts, the company aims to accelerate the discovery and development of new therapeutic candidates, expediting their journey from the lab to clinical application.
2. Personalized Medicine
- Objective: Century Therapeutics is committed to pioneering personalized medicine approaches in cell therapy. By utilizing iPSC technology and tailored therapies, the company seeks to address the unique biological and genetic characteristics of individual patients.
- Benefits: This focus maximizes treatment effectiveness and minimizes the risk of adverse reactions, thereby aligning with the broader trend toward personalized healthcare solutions.
3. Clinical Trials
- Commitment to Evidence: Conducting comprehensive clinical trials is crucial for validating the safety and efficacy of their therapies. Century Therapeutics collaborates with prominent medical centers to implement rigorous trial designs.
- Structure: These trials are meticulously structured to monitor the outcomes of cell therapies, following strict regulatory guidelines to ensure patient safety and scientific integrity prior to market introduction.
Summary
In summary, Century Therapeutics Inc. stands as a trailblazer in biotechnology, focusing on advanced iPSC technology and immune cell therapies to innovate treatment options for cancer and other diseases. Through their extensive product pipeline, cutting-edge CAR-macrophage platform, and proprietary manufacturing capabilities, the company is well-positioned to address pressing healthcare challenges. Their dedication to personalized medicine, robust research collaborations, and thorough clinical trials underscores their commitment to transforming regenerative medicine and improving patient outcomes.